Related Experiment Videos
Combined-modality therapy for inoperable non-small-cell lung cancer using gemcitabine
1Department of Radiation Oncology, Bodine Center for Cancer Treatment, Thomas Jefferson University Hospital, Philadelphia, PA 19107-5907, USA. walter.curran@mail.tju.edu
Clinical Lung Cancer
|January 15, 2004
Summary
Gemcitabine combined with radiation offers an effective treatment for advanced non-small-cell lung cancer, showing promising survival rates and response rates with manageable toxicity.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Combined-modality therapy (chemotherapy and radiation) is standard for locally advanced non-small-cell lung cancer (NSCLC).
- Traditional chemotherapy agents like cisplatin, vinblastine, and etoposide have been used in these regimens.
- Gemcitabine shows potential as a superior alternative due to comparable or improved efficacy and reduced toxicity.
Purpose of the Study:
- To evaluate gemcitabine in concurrent chemoradiotherapy for NSCLC.
- To explore modifications of gemcitabine-based chemoradiotherapy to optimize efficacy and minimize toxicity.
Main Methods:
- Concurrent chemoradiotherapy regimens incorporating gemcitabine.
- Modifications included dose reductions of gemcitabine and reduced radiation field sizes.
- Evaluation of patient outcomes, including survival and response rates.
Main Results:
- Gemcitabine sensitizes tumor cells to radiation and induces cells into the radioresistant S phase.
- Modified regimens with lower gemcitabine doses and smaller radiation fields maintained high efficacy.
- Achieved 1-year survival rates exceeding 50% and response rates up to 88%.
Conclusions:
- Gemcitabine-based concurrent chemoradiotherapy is a highly efficacious treatment for locally advanced NSCLC.
- Regimen modifications can successfully balance treatment efficacy with reduced toxicity.
- This approach represents a significant advancement in NSCLC management.